Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Group 1 - Corbus Pharmaceuticals Holdings Inc. is a clinical-stage company focused on oncology and obesity, with a commitment to innovative scientific approaches to serious illnesses [2] - The company will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference scheduled for January 12-15, 2026, in San Francisco, CA [1] - Corbus' pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 on cancer cells; CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation; and CRB-913, a CB1 inverse agonist for obesity treatment [2]